- In May 2024, Crinetics Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, announced positive Phase 3 results for paltusotine, its once-daily oral investigational drug for acromegaly. The study demonstrated strong efficacy in reducing IGF-1 levels while offering improved patient convenience over injectable therapies. This development marks a potential shift toward non-invasive treatment options and reinforces Crinetics’ role as a leader in endocrine disorder therapeutics
- In April 2024, Chiasma, Inc., now part of Amryt Pharma, expanded patient access to Mycapssa, the first and only FDA-approved oral somatostatin analog for acromegaly, through new pharmacy distribution agreements across the U.S. This expansion is aimed at increasing availability and affordability, particularly for patients seeking alternatives to long-acting injectable therapies, reflecting the market’s growing emphasis on patient-centered care
- In March 2024, Pfizer Inc. launched a new patient support initiative in the U.S. for individuals using Somavert (pegvisomant), a growth hormone receptor antagonist. The program includes financial assistance, home delivery options, and digital adherence tools to support long-term treatment compliance. This effort highlights Pfizer’s commitment to improving treatment experiences and reducing barriers to access for chronic endocrine conditions
- In February 2024, Ipsen Biopharmaceuticals introduced a real-world evidence program in collaboration with major U.S. endocrine centers to assess treatment outcomes and adherence patterns for Somatuline Depot. The initiative aims to generate actionable data that can help refine clinical practice and optimize therapy protocols, aligning with the broader industry trend toward evidence-based, individualized treatment strategies
- In January 2024, the Endocrine Society published updated U.S. clinical practice guidelines for the management of acromegaly, recommending earlier pharmacologic intervention for non-surgical candidates and expanded use of oral agents. These updated recommendations are expected to influence prescribing patterns and drive growth in the adoption of next-generation therapies across the U.S. healthcare landscape
